Predictive and prognostic implications of 4E-BP1, Beclin-1, and LC3 for cetuximab treatment combined with chemotherapy in advanced colorectal cancer with wild-type KRAS: Analysis from real-world data

Table 3 Univariate and multivariate analyses of the influence of Beclin1, LC3, 4E-BP1, and clinicopathological factors on survival in 45 patients with wild-type KRAS who were treated with cetuximab

	OS
	Univariate analysis		Multivariate analysis
	HR (95%CI)	P-value	HR (95%CI)	P-value
Sex	0.860 (0.452, 1.636)	0.496
Age	2.050 (0.831, 5.056)	0.111
Family	1.568 (0.786, 3.128)	0.198
Tumor location	0.933 (0.463, 1.880)	0.353
Pathological grade	2.273 (1.549, 3.335)	0.000	2.421 (1.397, 4.197)	0.002
T stage	1.240 (0.977, 1.573)	0.072	1.749 (1.190, 2.569)	0.004
N stage	1.159 (0.611, 2.200)	0.409
Synchronous/metachronous metastasis	1.493 (0.793, 2.813)	0.081
Beclin1 expression	0.466 (0.223, 0.971)	0.037	0.209 (0.064, 0.685)	0.010
LC3 expression	0.541 (0.262, 1.122)	0.094
4E-BP1 expression	2.926 (1.110, 7.713)	0.024	6.385 (1.764, 23.112)	0.005

Bold values indicate P < 0.05; tumor location, left side or right side. CI: Confidence interval; CRC: Colorectal cancer; HR: Hazard ratio; LC3: Microtubule-associated protein 1A/B-light chain 3; 4E-BP1: 4E-binding protein 1.